Akums Drugs and Pharmaceuticals Limited
680.20
INR
-13.85
(-2.00%)
ISIN
INE09XN01023
Return %
Stock
S&P 500
1Y
44.62
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Sanjeev Jain
- Full Time Employees
- 18,010
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Akums House, New Delhi DE India 110083
- IPO Date
- Aug 6, 2024
- Website
- akums.in
- Similar Companies
- Business
- Akums Drugs & Pharmaceuticals Ltd. (AKUMS.NS) operates as India's largest contract development and manufacturing organization (CDMO), specializing in the production of pharmaceutical formulations, active pharmaceutical ingredients (APIs), nutraceuticals, cosmeceuticals, and derma solutions for domestic and multinational clients; its core offerings encompass over 4,100 commercialized formulations across more than 60 dosage forms including tablets, capsules, injectables, soft gels, syrups, topicals, liquid orals, sterile parenterals, dry powder injections, hormonal preparations, oncology products, ayurvedic remedies, and animal healthcare solutions, targeting therapeutic segments such as cardio-diabetes, neurology, gynecology, nephrology, anti-infectives, respiratory, analgesics, and multi-vitamins. Founded in 2004 and headquartered in Delhi, India, the company maintains 15 state-of-the-art manufacturing facilities and four R&D centers—two approved by India's Department of Scientific and Industrial Research—supporting an annual capacity of 49.21 billion formulation units and 737.38 metric tons of APIs, with operations compliant to global standards including WHO-GMP, USFDA, EU-GMP, and TGA. Akums serves over 1,500 pharmaceutical partners worldwide, providing end-to-end services from formulation development and bioequivalence studies to clinical trials, regulatory support, and technology transfers. Recent developments include a December 2024 long-term contract valued at approximately ₹1,760 crore ($210 million) with a pharmaceutical firm for manufacturing formulations supplied to the European market, commercial operations commencing in 2027; an August 2025 framework agreement with the Government of Zambia to establish a joint venture manufacturing facility for oral solids, liquids, injectables, and beta-lactam products by 2028, preceded by $50 million in medicine purchases from Indian facilities during 2026-2027; a February 2025 announcement of ₹79 crore investment comprising ₹32 crore for a new Mumbai R&D hub and ₹47.5 crore for two dry powder injection lines; alongside facility acquisitions in Baddi (2023) and from Ankur Drugs (2022), a public listing on BSE and NSE in August 2024, and partnerships such as with Microcore Research (2024) for joint health supplements, Caregen and Jagdale for nutraceuticals/cosmeceuticals, and Triple Hair for alopecia treatments.